Total sales growth (fiscal Q4, period ended Jan. 31, 2026) -- 11%, on top of 10% growth in the prior year, demonstrating consecutive double-digit quarterly increases. Adjusted EPS (fiscal Q4) -- $4.99 ...

Operating Income -- $1.7 million, including $5.2 million in non-cash theater impairment charges; excluding these charges, operating income was $6.9 million, up 5.2% on an adjusted basis. Consolidated ...

Q4 2025 Earnings Call February 26, 2026 11:00 AM ESTCompany ParticipantsChad Paris - CFO & TreasurerGregory S.

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.